Therapeutic monoclonal antibodies for diabetic kidney disease: a narrative review from basic mechanisms to clinical evidence - Takeaways - MDSpire

Therapeutic monoclonal antibodies for diabetic kidney disease: a narrative review from basic mechanisms to clinical evidence

  • By

  • Xiu Hong Yang

  • Yao Liu

  • Chen Sheng Fu

  • Hui Min Jin

  • Zhi Bin Ye

  • July 9, 2026

  • 0 min

Share

  • 1

    Diabetic kidney disease (DKD) affects 20–40% of diabetes patients and is a leading cause of end-stage renal disease.

  • 2

    Monoclonal antibodies (mAbs) may target pathways involved in DKD, including TGF-β1, VEGF-B, and PCSK9.

  • 3

    Phase II studies of anti-TGF-β1 and anti-VEGF-B antibodies showed no significant renal benefits, revealing challenges in DKD treatment.

  • 4

    Anti-CTGF therapy indicated early signs of albuminuria reduction, while anti-suPAR is still under clinical evaluation.

  • 5

    Future mAb therapies for DKD require biomarker-informed patient selection and confirmation of intrarenal target engagement.

Original Source(s)

Therapeutic monoclonal antibodies for diabetic kidney disease: a narrative review from basic mechanisms to clinical evidence

  • by Xiu Hong Yang, Yao Liu, Chen Sheng Fu, Hui Min Jin, Zhi Bin Ye

  • July 9, 2026

Related Content

Efficacy and safety of abaloparatide, denosumab, teriparatide, oral bisphosphonates, and intravenous bisphosphonates in the treatment of postmenopausal osteoporosis: a systematic review and Bayesian network meta-analysis

Prediction models for progression from prediabetes to diabetes: a systematic review and meta-analysis

Recent progress in postoperative nausea and vomiting after thyroidectomy